Inspire Medical Systems (NYSE:INSP) demonstrates strong core gross economics with a 85.5% gross margin, $415.2 million in cash and investments, and a raised 2026 revenue guidance range of $835 million to $875 million. The company centers on its expanded patient reach, with over 140,000 patients treated, and its high-margin Inspire V system driving operational cash flow, offsetting short-term top-line headwinds while it works to secure long-term reimbursement clarity. However, as Inspire faces transitional coding hurdles, can a dominant sector titan leverage its category leadership to capture expanding market share despite rising competitive pressures? Find out here.
Inspire Medical Systems makes an implant for obstructive sleep apnea, and its sales are shrinking. Yet the stock trades at a forward P/E of 59.17, a multiple usually reserved for companies in the middle of a sprint. The company announced on October 1 that the AMA’s CPT Editorial Panel had approved new billing codes covering its latest device, a reimbursement milestone investors have been waiting on. The real question is how much of that good news the price already counts as banked.
Fatter Margins, Fresher Cash
The new Category I codes cover the Inspire V system and take effect on January 1, 2028. Dedicated codes should give hospitals and physicians a cleaner path to billing, which management expects to cut paperwork and widen patient access. Medicare still has to set a payment value for each code, and the company expects CMS to publish a proposed valuation in July 2027, with final numbers in November 2027. That matters because the US sales decline has been tied to a shifting coding and reimbursement environment.
Underneath, the business looks healthier than the top line suggests. Gross margin rose 150 basis points to 85.5% in the second quarter as more sales shifted to Inspire V, which earns more per device than its predecessor. Operating cash flow hit $23.2 million, up from $2.7 million a year earlier, helped by better handling of receivables and inventory. The company also raised its 2026 revenue outlook to a range of $835 million to $875 million, and it holds $415.2 million in cash and investments. Add more than 140,000 treated patients, and this is a company with a proven product, not one guessing at demand.
Meanwhile, as investors evaluate shifted product mixes across the sleep apnea device landscape, is a powerful market leader seeing its core business boom even as one key product stumbles? Click to read.
Shrinking Sales Meet Rich Pricing
Revenue fell 7.6% to $200.6 million in the second quarter. The US drove the decline, and international growth only partly cushioned it. Profit is razor-thin, with an operating loss of $0.5 million and GAAP diluted EPS of just $0.01. Management leans on adjusted EPS of $0.14, but the gap between adjusted and reported results deserves a close look. The company’s own full-year GAAP EPS guidance runs from a loss of $0.42 to a profit of $0.17, a range that straddles zero.
Fixing the business also costs money and time. Project Horizon, the restructuring plan, carries $20 million to $25 million of pre-tax charges and aims to free up roughly $30 million a year for growth spending. That only pays off if the redeployed dollars actually restart US sales. And with pricing for the new codes unsettled until late 2027, the reimbursement fog may linger for a while.
Skeptics Hold the Microphone
Hedge fund ownership slipped to 32 funds from 42 in the prior quarter, so institutions have been trimming rather than building positions. The forward P/E of 59.17, as of October 2, explains much of the hesitation. At that level, buyers are paying today for earnings that have not shown up yet, and with reported profit near zero, the multiple only works if you trust adjusted earnings, which the company guides at $1.05 to $1.45 for 2026.
Why would funds walk away from a company with margins this strong? Because a premium price leaves no room for sales to keep sliding while the reimbursement picture clears. Short interest sits at 17.79% of float, which signals heavy skepticism. It also means a crowded bet that could snap higher quickly if the news flow improves, though some of that shorting may be hedging rather than outright conviction.
Priced for a Turnaround
Inspire has strong gross economics, a clearer reimbursement road map, and a stock priced as if the road is already paved. The tension is timing, since the revenue decline is happening now while the payoff from the new codes sits well down the line. Bulls need US sales to stabilize and the reallocated restructuring dollars to earn a real return. Bears are watching for the CMS valuation to disappoint and for earnings to stay too thin to support the multiple.
READ NEXT: Top 10 AI Stocks That Will Skyrocket and 2 Stocks Trump Bought in July Are Now Down 17% to 20%. Time to Buy?
